---
document_datetime: 2025-12-29 11:11:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/upstelda.html
document_name: upstelda.html
version: success
processing_time: 0.0458854
conversion_datetime: 2025-12-30 01:52:15.591036
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Upstelda

[RSS](/en/individual-human-medicine.xml/246664)

##### Application withdrawn

The application for this medicine has been withdrawn

ustekinumab Medicine Human Application withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Key facts](#key-facts)
- [All documents](#all-documents)
- [Related information on withdrawals](#related-info-withdrawn)
- [News on Upstelda](#news-on)

- Application under evaluation
- Withdrawal of application

## Overview

The applicant withdrew the marketing authorisation application for Upstelda (ustekinumab) on 22 March 2024. It was a duplicate of the application for another medicine, Wezenla, which EMA's human medicines committee (CHMP) was evaluating in parallel, and which is not affected by this withdrawal.

Further details are included in the withdrawal letter.

## Key facts

Name of medicine Upstelda Active substance ustekinumab International non-proprietary name (INN) or common name ustekinumab Therapeutic area (MeSH)

- Psoriasis
- Arthritis, Psoriatic
- Crohn Disease

Anatomical therapeutic chemical (ATC) code L04AC05 EMA product number EMEA/H/C/006415 Marketing authorisation applicant Amgen Technology (Ireland) UC Withdrawal of application 22/03/2024

## All documents

Withdrawal assessment report for Upstelda

Adopted

Reference Number: EMA/250302/2024

English (EN) (2.96 MB - PDF)

**First published:** 30/07/2024

[View](/en/documents/withdrawal-report/withdrawal-assessment-report-upstelda_en.pdf)

Withdrawal letter : Upstelda

English (EN) (97.62 KB - PDF)

**First published:** 30/07/2024

[View](/en/documents/withdrawal-letter/withdrawal-letter-upstelda_en.pdf)

#### Related information on withdrawals

A question-and-answer (Q&amp;A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

#### News on Upstelda

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024) 26/04/2024

**This page was last updated on** 30/07/2024

## Share this page

[Back to top](#main-content)